OCV Partners is a Los Angeles based venture capital firm that invests in companies with differentiated technologies in compelling target markets.
With our decades of company-building experience, our overriding objective is to use our unique expertise to identify or create an asymmetric advantage when backing winning teams.
Our core focus sectors are Technology (SaaS, FinTech, and PropTech) and Healthcare (Therapeutics, Digital Health, and MedTech).

We are former Founders with a track record of success

We aim to create asymmetric advantages for our Founders

We are flexible capital – we like to lead, but it is not a requirement
Focus Sector: Technology
We invest in brilliant teams building disruptive technology. As former Founders, we have grown businesses from the earliest stages to IPOs and beyond. We invest in:
- Subscription software where we have expertise in growing and acquiring over 165 unique software companies
- Recurring revenue business models where our past experience reveals an asymmetric advantage
- SaaS, Fintech, and PropTech, which are areas where we have previously built companies
Focus Sector: Healthcare
We believe our investments should be challenging and changing what is possible for human health and disease.
We focus on entrepreneurs building disruptive platforms in Therapeutics, Digital Health, MedTech, and HealthIT.
We invest in companies that:
- Enable precision medicine or targeted therapies to improve patient lives
- Empower better treatment decisions and optimize workflows
- Remove barriers to care and improve equitable access
- Expedite the discovery of new treatments
Our deep technical and operational expertise uniquely positions us to invest in and support startups at the intersection of healthcare and technology.
News
ByHeart Announces the Launch of its Groundbreaking Infant Formula, Becoming the Only New Infant Formula Brand in Decades to Rewrite the Recipe From Scratch
After co-leading the $70M Series A alongside Polaris & D1 Capital and doubling down on the $90M Series B, OCV is incredibly proud to share that our portfolio company ByHeart is the first new infant formula manufacturer in over 15 years to be registered with FDA,...
Ockam Raises $12.5m Series A to Build a Remote-First, High-Performance Team
Ockam builds open-source developer-first tools for mutual authentication and end-to-end encrypted messaging between distributed applications, in any environment, anywhere… Trust Data-in-Motion. Ockam has secured $12.5 million of Series A funding from OCV,...
Rad AI Closes $25 Million Series A to Transform Radiology Workflow by Harnessing the Power of Artificial Intelligence
Rad AI, the fastest growing radiologist-led AI company, today announced $25 million in Series A funding. The round was led by Artis Ventures with participation from several existing investors, including OCV Partners, Kickstart Fund, and Gradient Ventures (Google's...
ByHeart Announces the Launch of its Groundbreaking Infant Formula, Becoming the Only New Infant Formula Brand in Decades to Rewrite the Recipe From Scratch
After co-leading the $70M Series A alongside Polaris & D1 Capital and doubling down on the $90M Series B, OCV is incredibly proud to share that our portfolio company ByHeart is the first new infant formula manufacturer in over 15 years to be registered with FDA,...
Ockam Raises $12.5m Series A to Build a Remote-First, High-Performance Team
Ockam builds open-source developer-first tools for mutual authentication and end-to-end encrypted messaging between distributed applications, in any environment, anywhere… Trust Data-in-Motion. Ockam has secured $12.5 million of Series A funding from OCV,...
With our decades of company building experience, we look to create asymmetric advantages when backing winning teams.